Toronto, Ontario–(Newsfile Corp. – March 10, 2023) – Optimind Pharma Corp. (CSE: OMND) (the “Company”) wishes to announce that pursuant to its stock option plan, it...
Optimind looks to accelerate the adoption of the MindSetting(TM) TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities. Toronto, Ontario–(Newsfile Corp. – September 20,...
Manitari Pharma received approval to begin construction of Security Level 3 safe plus grow rooms, Manitari Pharma is one step closer to obtaining Controlled Substances Dealer’s...
Toronto, Ontario–(Newsfile Corp. – August 4, 2022) – Optimind Pharma Corp. (CSE: OMND) (“Optimind” or the “Company”) today announced its commencement of trading on the CSE...